Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro

Hepatology

Volumn 26, Issue 1, 1997, Pages 216-225

  Colledge, Danni ^a   Locarnini, Stephen ^a   Shaw, Tim ^a  

^a FAIRFIELD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; LAMIVUDINE; PENCICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DUCK; HEPATITIS B; HEPATITIS B VIRUS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030926706     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260129     Document Type: Article

References (57)

1. Ayoola EA, Balayan MS, Deinhardt F, Gust I, Kureshi AW, Maynard JE, Nayak NC, et al. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Org 1988;66:443-455.
2. Lok A. Treatment of chronic hepatitis B. J Viral Hepat 1994;1:105-124.
3. Sherker A, Marion, P. Hepadnaviruses and hepatocellular carcinoma. Annu Rev Microbiol 1991;45:475-508.
4. Locarnini SA, Civitico GM, Newbold JE. Hepatitis B: new approaches for antiviral chemotherapy. Antiviral Chem Chemother 1996;7:53-64.
5. Shaw T, Locarnini, S. Hepatic purine and pyrimidine metabolism. Implications for chemotherapy in viral hepatitis. Liver 1995;15:169-184.
6. Sommadossi J-P. Treatment of hepatitis B by nucleoside analogs: still a reality. Curr Opin Infect Dis 1994;7:678-682.
7. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29: 403-415.
8. Wang G-H, Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 1992;71:663-670.
9. Zoulim F, Dannaoui E, Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. Abstracts of the 35th Interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society Microbiology, 1995:182.
10. Davis MG, Wilson JE, VanDraanen NA, Miller WH, Freeman GA, Daluge SM, Boyd FL, et al. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Res 1996;30:133-145.
11. Benhamou Y, Dohin E, Lunel-Fabiani F. Poynard T, Huraux JM, Katlama C, Opolon P, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995;345:397-397.
12. Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, Ruedy J, et al. A phase I/II study of 2′-deoxy-3′- thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995;171:1438-1447.
13. Chang CN, Skalski Y, Zhou JH, Cheng Y-C. Biochemical pharmacology of (+) and (-) 2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-22420.
14. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin MA. Preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
15. Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
16. Severini A, Liu X-Y, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-1-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995;39:1430-1435.
17. Tyrell DLJ, Fischer K, Cameron J. 2′,3′ Dideoxy 3′ thiacytidine (lamivudine) treatment of chimpanzees chronically infected with hepatitis B virus (HBV) results in rapid suppression of HBV DNA in sera. In: Program and Abstracts of the 18th International Symposium on Viral Hepatitis and Liver Disease. Viral Hepatitis Foundation of Japan. Tokyo, 1993:156.
18. Condreay LD, Condreay JP, Jansen RW, Pfaff MT, Averett DR. (-)cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob Agents Chemother 1996;40:520-523.
19. Soudeyns H, Yao X-J, Gao Q, Belleau B, Kraus J-L, Nguyen-Ba N, Spira B, et al. Anti-immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-1390.
20. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, Cameron JM. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992;36:1688-1694.
21. Civitico G, Wan YY, Luscombe C, Bishop N, Tachedjian G, Gust I, Locarnini, S. Antiviral strategies in hepatitis B virus infection. II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 1990;31:90-97.
22. Civitico G, Shaw T, Locarnini S. Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro. Antimicrobial Agents Chemother 1996;40:1180-1185.
23. Dean J, Bowden S, Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res 1995;27:171-178.
24. Luscombe C, Pedersen J, Bowden S, Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir therapy. Liver 1994;14:182-192.
25. Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic viral DNA, RNA, and protein expression. HEPATOLOGY 1996;24:776-773.
26. McMillan JS, Shaw T, Angus PW, Locarnini S. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. HEPATOLOGY 1995;22:36-43.
27. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994;38:719-723.
28. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1995;29:49-51.
29. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996;40:1282-1284.
30. Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S. The guanine nucleoside analogue penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40:413-418.
31. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhinition of HBV replication by penciclovir. HEPATOLOGY 1996;24:996-1002.
32. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749.
33. Ilsley DD, Lee S-H, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerases a, d and e with very different potencies and have unique mechanisms of action. Biochemistry 1995;34:2504-2510.
34. Fautz R, Husein B, Hechenberger C. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutation Res 1991;253:173-179.
35. Nakabayashi, H, Taketa K, Miyano K, Yamane K, Soto J. Growth of human hepatoma cell lines with differentiated functions in chemically defined media. Cancer Res 1982;42:3858-3862.
36. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47: 331-385.
37. Belen'kii MS, Schinazi RF. Multiple drug effect analysis with confidence interval. Antiviral Res 1994;25:1-11.
38. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
39. Martinez-Irujo JJ, Villahermosa ML, Alberdi E, Santiago E. A chequer-board method to evaluate interactions between drugs. Biochem Pharmacol 1996;51:635-644.
40. de Jong MD, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD. Consensus symposium on combined antiviral therapy. Antiviral Res 1995:29:5-29.
41. Civitico G, Locarnini, S. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 1994;203:81-89.
42. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:4398-4402.
43. Ling R, Mutimer D, Ahmed M, Boxall EH, Ellas E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
44. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 26: in press.
45. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human Immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-2234.
46. Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-1-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996;40:1957-1960.
47. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24:714-717.
48. Main J, Brown JL, Howells C, Galassini R, Karayiannis P, Georgiou P, Atkinson G, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996;3:211-215.
49. Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, et al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 1994;34:1199-1207.
50. White EL, Parker WB, Ross LJ, Shannon WM. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs. Antiviral Res 1994;22:295-308.
51. Xie, H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, Hosteller KY. Phosphatidyl-2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B- and HIV-1-infected cells. Antiviral Res 1995;28:113-120.
52. Shewach DS, Liotta DC, Schinazi RF. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem Pharmacol 1993;45:1540-1543.
53. Singhal RL, Abonyi M, Weber G. Nutritional and hormonal regulation of liver deoxycytidine kinase activity. Biochem Biophys Res Commun 1993;194:45-49.
54. Arner E, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995;67:155-186.
55. Bianchi V, Borella S, Caderazzo F, Ferraro P, Chieco-Bianchi L, Reichard P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci U S A 1994;91:8403-8407.
56. Heringa J, Argos P. Evolution of viruses as recorded by their polymerase sequences. In: Morse SS, ed. The Evolutionary Biology of Viruses. New York: Raven, 1994:87-103.
57. Girones R, Miller RH. Mutation rates of hepadnavirus genomes. Virology 1989;170:595-597.